Atlas-Backed Firm Will Seek Pan-Ataxia Therapy With Biogen’s Assistance
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen participates with Atlas Venture in a $17 million Series A financing for Ataxion, which will seek to advance preclinical ion channel modulators for hereditary ataxias.
You may also be interested in...
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
Financings of the Fortnight Wants To Spin You Right 'Round, And Out
Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.